Skip to main content
OpenTrials
Completed

NCT Number: NCT03947034

Monitoring the Hyperammonaemia:TOXicity of Drugs (AmmoTOX)

Several drugs and chemotherapies seem to have an impact on the metabolic system. This study investigates reports of metabolic toxicities such as hyperammonemia, including the International classification of disease ICD-10 for treatments in the World Health Organization (WHO) global Individual Case Safety Report (ICSR) database (VigiBase).

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Hyperammonemia Adverse Drug Event Chemically-Induced Disorders Drug Toxicity Drug-Related Side Effects and Adverse Reactions Metabolic Disease Metabolic Diseases Nutritional and Metabolic Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM

Paris, 75013, France

About this study

Several drugs and chemotherapies seem to have an impact on the metabolic system and are responsible of a wide range of metabolical side effects such as hyperammonemia. Those are poorly described, due to the modification of the pharmacopeia, and the recent recognition of several of these adverse events. This study investigates the main characteristics of patients affected by metabolic side effects imputed to drugs in particular hyperammonemia. A causality assessment according to the WHO-UMC (World Health Organization - Uppsala Monitoring Center) is systematically applied.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Case reported in the WHO's pharmacovigilance database till 01/05/2019

Exclusion criteria

  • Chronology not compatible between the drug and the toxicity

Treatment and study plan

Drugs inducing hyperammonemia

Drug

Drugs susceptible to induce metabolic toxicities such as hyperammonemia

Primary outcomes

  1. Metabolic toxicities (such as hyperammnemia) of drugs Identification and report of cases of metabolic toxicities associated with drugs.

    Time frame: to 01/05/2019

    Case reported in the World Health Organization (WHO) database of individual safety case reports

Secondary outcomes

  1. Causality assessment of reported metabolic toxicities events according to the WHO system

    Time frame: to 01/05/2019

    Case reported in the World Health Organization (WHO) database of individual safety case reports

  2. Description of the type of metabolic toxicity depending on the category of drug

    Time frame: to 01/05/2019

    Case reported in the World Health Organization (WHO) database of individual safety case reports

  3. Description of the other immune related adverse events concomitant to the metabolic toxicity induced by drugs

    Time frame: to 01/05/2019

    Case reported in the World Health Organization (WHO) database of individual safety case reports

  4. Description of the duration of treatment when the toxicity happens (role of cumulative dose)

    Time frame: to 01/05/2019

    Case reported in the World Health Organization (WHO) database of individual safety case reports

  5. Description of the drug-drug interactions associated with adverse events

    Time frame: to 01/05/2019

    Case reported in the World Health Organization (WHO) database of individual safety case reports

  6. Description of the pathologies (cancer) for which the incriminated drugs have been prescribed

    Time frame: to 01/05/2019

    Case reported in the World Health Organization (WHO) database of individual safety case reports

  7. Description of the population of patients having hematological toxicity adverse event

    Time frame: to 01/05/2019

    Case reported in the World Health Organization (WHO) database of individual safety case reports

Sponsors and collaborators

Lead sponsor

Groupe Hospitalier Pitie-Salpetriere

Other

Registry information

Acronym: AmmoTOX

Important dates

Study start
2019
Primary completion
2020
Study completion
2023
First posted
May 13, 2019
Registry last updated
Apr 5, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.